Literature DB >> 12882658

CD4+ and CD8+ T cell receptor repertoire perturbations with normal levels of T cell receptor excision circles in HIV-infected, therapy-naive adolescents.

Savita Pahwa1, Vivek Chitnis, Richard M Mitchell, Sanjit Fernandez, Alamelu Chandrasekharan, Craig M Wilson, Steven D Douglas.   

Abstract

Our objective was to determine whether treatment-naive HIV-infected adolescents manifest abnormalities in thymus function and peripheral T cell repertoire, and to assess relationships of these immunologic characteristics with each other, with plasma HIV virus load, and T cell surface markers. TCR Vbeta repertoire was determined by CDR3 length spectratyping in purified CD4(+) and CD8(+) T cells of high-risk, HIV-negative adolescents and of treatment-naive, HIV-infected adolescents. Thymus function was investigated by the simultaneous examination of T cell receptor excision circles (TRECs) in the CD4(+) and CD8(+) T cell subsets. HIV-infected adolescents exhibited significantly greater perturbations in their TCR Vbeta repertoire in comparison with HIV-negative subjects. Perturbations in the CD8(+) T cell compartment were more profound in comparison with CD4(+) T cells. The CD4(+) TCR Vbeta perturbations were negatively correlated with the total and phenotypically naive CD4(+) T cells, and with CD4(+) TRECs. CD8(+) TRECs, although not correlated with CD8(+) TCR Vbeta perturbations, showed negative correlation with memory and activated CD8(+) T cells. Interestingly, TRECs in CD4(+) and CD8(+) T cells were not significantly different between HIV-infected and uninfected adolescents. The TCR Vbeta repertoire in adolescents is profoundly perturbed even in early stages of HIV infection, when total CD4(+) cell counts in most subjects are within normal limits. The correlative analyses demonstrating negative association of CD4(+) cell TRECs with CD4(+) TCR Vbeta perturbations and of CD8(+) TRECs with CD8(+) cell activation markers provide evidence of the intense activation of the central and peripheral immune compartments in this study population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882658     DOI: 10.1089/088922203766774531

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Simplified fluorescent multiplex PCR method for evaluation of the T-cell receptor V beta-chain repertoire.

Authors:  Sanjit Fernandes; Surendra Chavan; Vivek Chitnis; Nina Kohn; Savita Pahwa
Journal:  Clin Diagn Lab Immunol       Date:  2005-04

2.  Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie.

Authors:  Kellie N Smith; Robbie B Mailliard; Charles R Rinaldo
Journal:  For Immunopathol Dis Therap       Date:  2015

3.  Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents.

Authors:  Li Yin; Zhong Chen Kou; Carina Rodriguez; Wei Hou; Maureen M Goodenow; John W Sleasman
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

4.  The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo.

Authors:  Liljana Stevceva; Victor Yoon; Angela Carville; Beatriz Pacheco; Michael Santosuosso; Birgit Korioth-Schmitz; Keith Mansfield; Mark C Poznansky
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

5.  Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life.

Authors:  S Paghera; E Quiros-Roldan; A Sottini; M Properzi; F Castelli; L Imberti
Journal:  Immun Ageing       Date:  2019-10-13       Impact factor: 6.400

6.  Limited T cell receptor repertoire diversity in tuberculosis patients correlates with clinical severity.

Authors:  Wei Luo; Jin Su; Xiao-Bing Zhang; Zhi Yang; Ming-Qian Zhou; Zhen-Min Jiang; Pei-Pei Hao; Su-Dong Liu; Qian Wen; Qi Jin; Li Ma
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.